122 related articles for article (PubMed ID: 11881537)
1. Satraplatin. BMS 182751, BMY 45594, JM 216.
Drugs R D; 2002; 3(1):67-71. PubMed ID: 11881537
[No Abstract] [Full Text] [Related]
2. Satraplatin: BMS 182751, BMY 45594, JM 216.
Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
[TBL] [Abstract][Full Text] [Related]
3. Satraplatin: leading the new generation of oral platinum agents.
Bhargava A; Vaishampayan UN
Expert Opin Investig Drugs; 2009 Nov; 18(11):1787-97. PubMed ID: 19888874
[TBL] [Abstract][Full Text] [Related]
4. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation.
McKeage MJ
Drugs; 2007; 67(6):859-69. PubMed ID: 17428104
[TBL] [Abstract][Full Text] [Related]
5. Satraplatin: an orally available platinum analog for the treatment of cancer.
Choy H
Expert Rev Anticancer Ther; 2006 Jul; 6(7):973-82. PubMed ID: 16831070
[TBL] [Abstract][Full Text] [Related]
6. An update on satraplatin: the first orally available platinum anticancer drug.
Kelland LR
Expert Opin Investig Drugs; 2000 Jun; 9(6):1373-82. PubMed ID: 11060749
[TBL] [Abstract][Full Text] [Related]
7. Current status and future prospects for satraplatin, an oral platinum analogue.
Choy H; Park C; Yao M
Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
[TBL] [Abstract][Full Text] [Related]
10. Satraplatin for hormone-refractory prostate cancer.
Kerr C
Lancet Oncol; 2007 Apr; 8(4):290. PubMed ID: 17431954
[No Abstract] [Full Text] [Related]
11. ZD-0473 AstraZeneca.
Hay MP
Curr Opin Investig Drugs; 2000 Oct; 1(2):263-6. PubMed ID: 11249584
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of patients with intestinal cancer. Increased neurotoxicity after oxaliplatin and related liver metastasis].
Junker A; Kretzschmar A; Böhm U; Tannapfel A; Langenbahn D; Pieck AC; Jaehde U
Med Monatsschr Pharm; 2004 Oct; 27(10):349-52. PubMed ID: 15527179
[No Abstract] [Full Text] [Related]
13. Oxaliplatin: a review of evolving concepts.
Mani S; Graham MA; Bregman DB; Ivy P; Chaney SG
Cancer Invest; 2002; 20(2):246-63. PubMed ID: 11901545
[No Abstract] [Full Text] [Related]
14. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism of action and pharmacology of new organometallic compounds active in the treatment of colorectal neoplasms].
Marchetti P; Gallà DA; Cifone G; Ricevuto E; Ficorella C
Tumori; 2000; 86(3 Suppl):S6-8. PubMed ID: 10969607
[No Abstract] [Full Text] [Related]
16. Oxaliplatin in colorectal cancer: an overview.
Armand JP; Boige V; Raymond E; Fizazi K; Faivre S; Ducreux M
Semin Oncol; 2000 Oct; 27(5 Suppl 10):96-104. PubMed ID: 11049040
[No Abstract] [Full Text] [Related]
17. Carboplatin: the clinical evaluation strategy.
Rozencweig M; Canetta R; Carter SK
Cancer Treat Rev; 1985 Sep; 12 Suppl A():137-44. PubMed ID: 3910217
[No Abstract] [Full Text] [Related]
18. CL 287,110 and CL 286,558.
Cancer Invest; 1989; 7(5):537. PubMed ID: 2620257
[No Abstract] [Full Text] [Related]
19. [Oxaliplatin in colorectal cancer].
Boni C; Banzi M
Tumori; 2001; 87(1 Suppl 1):S51-2. PubMed ID: 11300025
[No Abstract] [Full Text] [Related]
20. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Ricart AD; Sarantopoulos J; Calvo E; Chu QS; Greene D; Nathan FE; Petrone ME; Tolcher AW; Papadopoulos KP
Clin Cancer Res; 2009 Jun; 15(11):3866-71. PubMed ID: 19458055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
